Portfolio Lab

Progyny, Inc.

  • Stock
  • Ticker PGNY
  • Nasdaq

Health care · Health care services · USA

$35.71 +0.73%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Progyny, Inc. since 10/2019, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

PGNYGlobal equities (VT)

$10,000 grew to $5,813. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −79.5% in 11/2024, measured from the peak in 11/2021. The old peak has not been reached again yet.

1-year return
+43.8%
5-year return p.a.
−9.7%
Return p.a. since 10/2019
+12.1%
Volatility p.a.
57.1%
Largest decline
−79.5%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue298324333313318329351341
Gross profit6376797377838984
Operating income1624242215354035
EBITDA1725262317374237
Net income1115171412242826
Earnings per share0.120.170.190.150.140.290.340.32
Balance sheet
Total assets607730761795742698716676
Liabilities185263246235226259263262
Equity422467515560516439453414
Cash162109133134112132153117
Cash flow
Operating cash flow5250565154465057
Capital expenditure-1.9-2.8-5.3-4.7-5.6-6.3-6.2-9.4
Free cash flow5047504649404447

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +54.4%, weakest 2024 at −53.6%. 4 of 6 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
5 Nov 2026$0.32
7 Aug 2026$0.34
8 May 2026$0.29
27 Feb 2026$0.14
7 Nov 2025$0.15
8 Aug 2025$0.19
9 May 2025$0.17
3 Mar 2025$0.12
12 Nov 2024$0.11
7 Aug 2024$0.17
10 May 2024$0.17
29 Feb 2024$0.13

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€2.4bn
Market cap in trading currency
$2.63bn
Enterprise value
$2.43bn
P/E
32.8
P/S
1.96
P/B
6.35
EV/Sales
1.82
EV/EBITDA
18.4
Earnings yield
3.1%
FCF yield
6.8%

Results (last four quarters)

Revenue
$1.34bn
Gross profit
$333m
EBITDA
$132m
Net income
$91.0m
Earnings per share
$1.09
Revenue per share
$18.18
Revenue growth
+8.9%
Earnings growth
+89.4%

Profitability

Gross margin
24.9%
Operating margin
9.4%
Net margin
6.8%
Return on equity
18.7%
Return on assets
13.5%

Balance sheet and cash flow

Cash
$196m
Cash per share
$2.66
Financial debt
–
Debt/equity %
–
Current ratio
1.93
Book value per share
$5.62
Operating cash flow
$207m
Free cash flow
$180m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
73.6m
Volume
1.11m
Avg. volume 3 months
1.11m
Relative volume
1.0

Price and technicals

Price
$35.71
1 day
+0.7%
52-week high
$37.15
52-week low
$16.30
Distance to 52-week high
−3.9%
Distance to 52-week low
+119.1%
Distance to 50-day line
+21.4%
Distance to 200-day line
+42.0%
RSI (14)
68
Volatility 1M
53.0%

Performance

1 week
−1.3%
1 month
+22.6%
3 months
+40.3%
6 months
+43.5%
YTD
+39.1%
1 year
+40.6%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has PGNY performed since 10/2019?

$10,000 grew to $22,403 by 20 Nov 2026, which is +12.1% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is PGNY?

Volatility was 57.1% per year, measured on monthly returns. The largest decline from a peak was −79.5%, with the low in 11/2024.

How does PGNY compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 16.4% volatility, PGNY returned +12.1% at 57.1%. The correlation of monthly returns was 0.31; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Progyny, Inc. (PGNY): Return and risk | Portfolio Lab